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Abstract 22 
The advent of technologies to genetically manipulate the mouse genome has revolutionised research 23 
approaches, providing a unique platform to study the causality of reproductive disorders in vivo. With 24 
the relative ease of generating genetically modified mouse models, the last two decades have yielded 25 
multiple loss-of-function and gain-of-function mutation mouse models to explore the role of 26 
gonadotrophins and their receptors in reproductive pathologies. This work has provided key insights 27 
into the molecular mechanisms underlying reproductive disorders with altered gonadotrophin action, 28 
revealing the fundamental roles of these pituitary hormones and their receptors in the hypothalamic-29 
pituitary-gonadal axis. This review will describe genetically modified mouse models of gonadotrophins 30 
and their receptors with enhanced or diminished actions, specifically focussing on the male. We will 31 
discuss the mechanistic insights gained from these models into male reproductive disorders, and 32 
discuss the relationship and understanding provided into male human reproductive disorders 33 
originating from altered gonadotrophin action. 34 
 35 
1. Introduction 36 
The precise control of the hypothalamic-pituitary-gonadal axis is essential for coordinating and 37 
maintaining reproductive functions. In response to the pulsatile release of hypothalamic 38 
gonadotrophin-releasing hormone (GnRH), the synthesis and secretion of the pituitary gonadotrophic 39 
hormones, luteinising hormone (LH) and follicle-stimulating hormone (FSH), modulates testicular 40 
function through the binding and activation of the gonadotrophin receptors, luteinising 41 
hormone/chorionic gonadotrophin receptor (LHCGR or LHR)
1
 and FSH receptor (FSHR) respectively. 42 
The downstream activity of the gonadotrophin receptors is critical for initiation and maintenance of 43 
gonadal steroidogenesis and for support, production and maturation of viable germ cells. Our 44 
understanding of gonadotrophic hormone/gonadotrophin receptor biology has been greatly enhanced 45 
by the generation and study of genetically modified (GM) mouse models. The advent of GM mouse 46 
                                                            
1
 The luteinising hormone/chorionic gonadotrophin receptor, abbreviated as LHCGR or LHR, is the official gene, 
derived from the two endogenous ligands of LHR, LH and chorionic gonadotrophin (CG), in CG secreting 
species e.g., humans and horses.  
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models, with their relative ease in generation, coupled with short gestation time and life-cycle relative 47 
to larger mammalian species, have provided a powerful tool to study reproductive disorders. 48 
Moreover, the study of GM mouse models has provided key molecular insight into the causality and 49 
contributions of gonadotrophic hormones and their cognate receptors to human reproductive 50 
pathologies. A number of GM approaches have been taken to understand the molecular mechanisms 51 
governing reproductive pathologies; gain-of-function approaches have utilised the over-expression of 52 
gonadotrophins or the generation of constitutively activating mutations (CAM) of gonadotrophin 53 
receptors, while loss-of-function approaches have relied upon knock-out technology to remove/silence 54 
gonadotrophin receptor or gonadotrophin gene expression. This review will describe GM mouse 55 
models with direct genetic modifications in gonadotrophin subunits or gonadotrophin receptors. We 56 
will discuss the implications of these findings on male reproductive function, and the important 57 
insights these models provide into human health and disease.  58 
 59 
2. GM models of altered gonadotrophin action 60 
The functional role of the testis is two-fold; the production of male gametes and androgen support, 61 
primarily through testosterone secretion for local androgenic action, for stimulation and maintenance 62 
of spermatogenesis and extra-gonadal sexual and anabolic functions (McLachlan, et al. 1995, 63 
Sharpe, et al. 1994). In the postnatal mouse, the coordinated and temporal release of the 64 
gonadotrophins, LH and FSH, are required for the differentiation and maturation of the testis and 65 
extragonadal sex organs; LH is necessary for the production and secretion of testosterone via the 66 
Leydig cells, although minimal tonic testosterone production is observed in the absence of LH/LHR 67 
function, while FSH is responsible for the maintenance of spermatogenesis by stimulation and 68 
maintenance of a multitude of Sertoli cell functions.  69 
 70 
2.1 Enhanced LH-LHR activity 71 
To examine the effects of promiscuous LHR activation, our laboratory generated two transgenic 72 
mouse models with enhanced LH/human chorionic gonadotrophin (hCG) action. The first model 73 
generated expressed the hCGβ subunit under the human ubiquitin C promoter, allowing ubiquitous, 74 
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persistent, and low-level expression of hCGβ from late gestation onwards (Rulli, et al. 2003). The 75 
rationale behind this was that when the transgene was co-expressed in pituitary gonadotroph and 76 
thyrotroph cells with the glycoprotein hormone common α-subunit (αGSU), bioactive heterodimers α/β 77 
hCG would be produced. We termed this model hCGβ, and in males, it attained moderately 3-4-fold 78 
elevated levels of bioactive hCG compared to endogenous LH (Rulli, et al. 2003). hCGβ+ males were 79 
fertile with full spermatogenesis and normal sperm quality despite reduced testis size and serum FSH 80 
(Rulli, et al. 2003), echoing the phenotype observed in activating LHR mutations in humans. However, 81 
the onset of puberty was normal, with no evidence of precocious puberty, which is the hallmark of 82 
human males with enhanced LHR activation (Themmen and Huhtaniemi 2000). As modest elevation 83 
in LH/hCG action had no effect on fertility or the timing of puberty, we went on to test the effect of 84 
grossly elevated LH/hCG on these factors. To achieve this, we generated another mouse model 85 
expressing the αGSU, also under the human ubiquitin C promoter when crossed with the hCGβ+ 86 
mice, creating a double transgenic line (hCGαβ+), with a 1000-fold higher circulating concentration of 87 
bioactive LH/hCG observed than in wild-type (WT) mice (Rulli, et al. 2003). hCGαβ+ males were 88 
infertile, despite exhibiting comparable spermatogenesis as evidenced by histological analysis of 89 
testis and caudal epididymal sperm motility and morphology to hCGβ+ and WT littermates. Infertility 90 
appeared to be mechanical and/or behavioural in origin, with hCGαβ+ males displaying extremely 91 
aggressive behaviour, often resulting in severe injury or death of WT females housed with the males, 92 
and mating ability impaired as evidenced by the lack of vaginal plugs during breeding studies.  Testes 93 
size was smaller with enlarged seminal vesicles and prostate, dilated vasa deferentia and bladder, as 94 
well as kidney defects in adulthood (Rulli, et al. 2003). Testicular steroidogenesis was also enhanced, 95 
despite a near total down-regulation of cell surface LHR expression, echoing studies showing that 96 
less than 0.1% occupation of LHR is required for full testicular steroidogenesis (Mendelson, et al. 97 
1975). As with hCGβ+ males, precocious puberty was not detected in hCGαβ+ males, despite highly 98 
elevated serum testosterone with the timing of the balano-preputial separation and onset of 99 
spermatogenesis indistinguishable from WT males (Ahtiainen, et al. 2005). Interestingly, juvenile 100 
hCGαβ+ males developed Leydig cell adenomas, reaching their maximum size at 10 days postpartum 101 
but disappearing by puberty, coinciding with the normal regression pattern of fetal Leydig cells. The 102 
gene expression of fetal and adult Leydig cell markers suggested that the adenomas originated from 103 
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the fetal Leydig cell population, providing evidence that the adult Leydig cells may be resistant to 104 
developing gonadotrophin-induced adenomas (Ahtiainen, et al. 2005).  105 
 106 
Recent studies of the hCGαβ+ animals, have revealed that the hypothalamic function of prepubertal 107 
males was altered, displaying accelerated GnRH pulse frequency and increased GnRH content of 108 
GnRH neurons, coupled to decreased pituitary expression of GnRH receptor (Gonzalez, et al. 2011). 109 
A profound and persistent malfunction of the neuroendocrine feedback control of the gonadotrophin 110 
axis was evidenced, with FSH levels persistently low throughout life and unresponsive to castration or 111 
the anti-androgen flutamide both pre and postpubertally, but with re-establishment by blockade of 112 
perinatal androgen action (Gonzalez, et al. 2011). These findings suggest that androgen excess, 113 
during a critical window between gestational day 18 and postnatal day 14, is able to disrupt the 114 
developmental programming of the male hypothalamic-pituitary-gonadal axis. A direct testosterone-115 
dependent regulation of hypothalamic aromatase expression was also demonstrated, indicating that 116 
locally produced oestrogens might play a key role in the hypothalamic–pituitary phenotype of hCGαβ+ 117 
mice. 118 
 119 
Additional GM models to test the effects of elevated hCG or LH have also been utilised by others. A 120 
transgenic model over-expressing hCGβ expressed under the metallothionein (MT-1) promoter did 121 
not show elevated circulating dimeric hCG nor obvious changes in testicular phenotype, yet MT-1-122 
hCGβ males were infertile, speculated to be due to free circulating hCGβ subunit binding to LHR and 123 
competing with endogenous LH for receptor occupancy (Matzuk, et al. 2003). Co-expression of MT-1-124 
hCGα and hCGβ subunits was conducted, to form the active hCG heterodimer. Male mice with low 125 
expression of MT-1-hCGαβ were initially fertile and indistinguishable from WT littermates. However, 126 
by 6-7 months, these mice were progressively infertile but no histological abnormalities were 127 
observed or obvious phenotypic explanation to indicate the cause of infertility. Male mice with high 128 
expression of the MT-1-hCGαβ transgenes, as with ubiquitin C-expressed hCGαβ+ male mice, were 129 
infertile, the origin of which appearing to be through disrupted mating behaviour as evidenced by lack 130 
of vaginal plugs when housed with either super-ovulated or naturally cycling female mice. Male mice 131 
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were also noted to be aggressive when caged with other male or female mice, and displayed altered 132 
sexual behaviour. Serum testosterone was highly elevated, and circulating gonadotrophins 133 
decreased. Testis size was reduced, and histological analyses showed Leydig cell hyperplasia and in 134 
some tubules sertoli-cell only like syndrome, with germ cell loss, echoing observation of LHR over-135 
activity in humans. A transgenic model for elevated LH consisting of a fusion protein of the bovine 136 
LHβ subunit and the hCGβ C-terminal peptide (bLHβ-CTP) under the common α- subunit promoter 137 
has also been studied. However this model failed to produce sufficiently elevated LH/hCG bioactivity 138 
in male animals, as they presented with no apparent phenotype (Risma, et al. 1995).  139 
 140 
To constitutively activate LHR, a novel transgenic approach using covalently linked hCGβ and αGSU 141 
to reconstitute heterodimeric hCG, fused to rat LHR expressed under inhibin-α subunit promoter, 142 
termed ‘yoked’ LHR (YHR), was utilised (Meehan, et al. 2005, Meehan and Narayan 2007). In pre-143 
pubertal males, enhanced LH/LHR action was observed, with increased circulating testosterone and 144 
seminal vesicle weights, probably due to the early expression of the transgene driven by the inhibin-α 145 
promoter. However, despite this elevation in testosterone, as with the hCGβ+ and hCGαβ+ animals, 146 
the timing of puberty was normal. Post-puberty, there was a trend for enhanced LHR action, with 147 
decreased seminal vesicle weights and reduced testis size due to a decrease in seminiferous tubule 148 
volume. However, normal spermatogenesis was noted. As with hCGβ+ animals, serum FSH was 149 
supressed in both pre- and postpubertal animals, however LH was only suppressed in pre-pubertal 150 
animals. This defect, may be the consequence of a dysregulation in hypothalamic-pituitary 151 
communication, and may reflect differences in the regulation of LH and FSH secretion.   152 
 153 
To date, a single constitutively activating mutation (CAM) LHR mouse model has been described, the 154 
result of a knock-in D582G LHR mutation, the most commonly observed CAM mutation in human 155 
boys with familial male-limited precocious puberty (McGee and Narayan 2013). As with the human 156 
mutation, D582G LHR resulted in precocious puberty, with decreased testis weight and increased 157 
seminal vesicle weight at 3 weeks post-partum. Serum and intra-testicular testosterone were 158 
increased from day 7 post-partum; however serum FSH and LH remained below the limit of detection 159 
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throughout the tested life-span of the animals, due to steroid hormone feedback. Sertoli cell 160 
development was unaltered, however Leydig cell hyperplasia was observed, with enhanced 161 
expression of steroidogenic genes in most age groups tested. Although precious puberty was 162 
observed, spermatogenesis was not altered in these male mutants. Although initially fertile, 163 
progressive infertility was detected, but normal levels of epididymal sperm were noted, indicating a 164 
potential abnormality in seminal vesicle and prostate function and/or lower urinary tract, however 165 
detailed analysis of accessory gland function was not carried out.  166 
 167 
 168 
2.2 Enhanced FSH-FSHR activity 169 
GM mouse models with elevated FSH have been generated to explore enhanced ligand-dependent 170 
activation of FSHR. As with MT-hCGβ, and MT-hCGαβ, Kumar et al took the approach of 171 
overexpressing human αGSU, and the human FSHβ subunit under the MT-1 promoter. The MT-1-172 
αGSU and MT-1-FSHβ transgenic mice were fertile. Inter-crossing of these transgenic mouse strains 173 
generated mice over-expressing dimeric FSH (MT-1-FSHαβ), with high levels of circulating FSH. Male 174 
mice were largely infertile, with just 1 in 10 animals producing 1 litter of pups in a 6 month period. 175 
Mating studies suggested a lack of mating activity in these animals. Testicular size and morphology 176 
was indistinguishable from WT, like wise epididymal weights were comparable. However, serum 177 
testosterone was elevated and seminal vesicles enlarged, due to increased androgenic action. 178 
Histological analysis of the testes showed little difference from WT, moreover, analysis of epididymal 179 
sperm numbers showed MT-1-FSHαβ animals to have increased sperm number, with no difference in 180 
motility or viability. These findings suggest that the infertility observed in MT-1-FSHαβ animals 181 
appears to result from behaviour changes rather than a direct impact on spermatogenesis. It is 182 
possible that the increase in testosterone resulted in altered and/or aberrant seminal vesicle 183 
secretions, or functional incompetence of the sperm.   184 
 185 
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Mouse models of enhanced FSHR activity have primarily utilised the hpg mouse model as a 186 
background in which to generate the mutations. The hpg mouse, resulting from a naturally occurring 187 
deletion mutation in GnRH (Cattanach, et al. 1977), with a phenotype of hypogonadotrophic 188 
hypogonadism, provides the advantage of testing the effects and direct contribution of FSH/FSHR-189 
dependent testicular function, in the absence of circulating LH and activation of LHR. Using the rat 190 
androgen binding protein promoter for specific integration into Sertoli cells, Haywood et al created a 191 
transgenic line expressing the human Asp567Gly mutation FSHR CAM (TG-FSH+) (Haywood, et al. 192 
2002). Testicular expression was confirmed, and enhanced ligand independent cAMP production 193 
detected in cultured TG-FSH+ Sertoli cells. In a WT background, testis weights and fertility were 194 
comparable between TG-FSH+ animals and WT littermates. However, in the hpg background, testis 195 
weights were significantly increased in comparison to hpg littermates, moreover, treatment with 196 
testosterone at equivalent levels to the maximum observed in hpg mouse testis, vastly increased 197 
testis size in hpg TG-FSH+ animals in comparison to hpg littermates. Histological analysis of the 198 
testes showed the presents of both round and elongated spermatids, and examination of Sertoli cell 199 
structure showed the maturation of this cell type. Although intra-testicular testosterone was increased 200 
in hpg TG-FSHR+ animals, serum testosterone was no different from hpg littermates. A similar 201 
phenotype was also observed in a transgenic model over-expressing complete FSH (αGSU and 202 
FSHβ subunits) in a WT or hpg mouse background (Allan, et al. 2001), showing that without LH-203 
induced testosterone production, FSH/FSHR activity is sufficient for Sertoli cell maturation and can 204 
promote spermatogenesis to some extent. However, LH/LHR activity, and consequential testosterone 205 
production, is required for the completion of spermiogenesis. 206 
 207 
In our laboratory, a knock-in constitutively activating mFshrD580H mouse model has been generated 208 
(Oduwole/Peltoketo et al, manuscript in preparation). Interestingly, despite this mutation having 209 
deleterious effects on female reproduction (Peltoketo, et al. 2010), male animals did not present with 210 
any obviously altered phenotype during embryogenesis, puberty or adulthood. The gross morphology 211 
and histology of the reproductive tract and testis appeared no different to WT littermates, showing that 212 
enhanced FSHR activity alone in the WT background, as opposed to hpg mice, had neither positive 213 
nor deleterious effects on male reproductive function.  214 
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 215 
2.3 Diminished LH-LHR activity 216 
The first GM approach exploring the effects of loss of function of gonadotrophins utilised deletion of 217 
αGSU. Deletion of the αGSU gene in male mice showed normal pre-natal and pre-pubertal sexual 218 
differentiation and gonadal development, confirming that pre-pubertal gonadal development in mice is 219 
independent of gonadotrophin action (Kendall, et al. 1995). However, male animals, being also 220 
hypothyroid, failed to undergo puberty, and exhibited a lack of sex steroid production. Post pubertal 221 
animals lacked gonadal development and function, with diminished testis size and smaller 222 
seminiferous tubules, and spermatogenesis blocked at the first meiotic division. The presence of vas 223 
deferens and epididymis showed that the αGSU KO mice were able to produce sufficient testosterone 224 
in utero. As the αGSU gene is an integral part of both heterodimeric thyroid stimulating hormone 225 
(TSH), and FSH, it should be noted that phenotypic effects observed from deletion of αGSU are not 226 
just the result of lacking LH action, but also TSH and FSH action. The mouse model demonstrated 227 
that mice devoid of glycoprotein hormone production are viable, which is perhaps not unsurprising 228 
given that mice do not express or secrete placental CG, and rather rely upon placental lactogens and 229 
alternative hormonal support for maintenance of pregnancy, in contrast to humans in whom hCG is 230 
vital. 231 
 232 
To decipher the effects of deleting LHR, our laboratory took the approach of generating an LHR 233 
knockout (LuRKO) mouse. As with the αGSU knockout mice, LHR deletion resulted in alterations of 234 
the reproductive tract from the pubertal period onwards, exhibiting normal pre-pubertal development 235 
(Zhang, et al. 2004). Elevated FSH and LH were observed, with a decrease in sex steroid 236 
concentrations, due to lack of steroid feedback to the hypothalamic-pituitary axis (Pakarainen, et al. 237 
2007). Adult LuRKO males were infertile with underdeveloped testes and hypoplastic accessory sex 238 
organs. Testes were cryptorchid and significantly reduced in size, with narrow seminiferous tubules, 239 
decreased number and size of Leydig cells and arrested spermatogenesis at the round spermatid 240 
stage. The expression of Leydig cell specific genes, whilst similar at birth, became gradually low or 241 
undetectable in adulthood. Accessory sex organs, including the prostate and seminal vesicles, were 242 
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undetectable (Lei, et al. 2001, Zhang, et al. 2001). A similar phenotype to the LuRKO mice was also 243 
observed with the deletion of LHβ, mimicking the reproductive phenotypes displayed in αGSU null 244 
male mice (Ma, et al. 2004), however knock-out LHβ males exhibited unaltered serum FSH, 245 
contrasting from the hypogonadotrophic and hypergonadotrophic phenotypes of αGSU and LuRKO 246 
male mice respectively. 247 
 248 
An interesting difference that exists between human and mouse inactivating LHR mutations, is that 249 
normal pre-pubertal development is observed in male mice, however, in human counterparts, 250 
complete inactivation of LHR results in pseudohermaphroditism (Themmen and Huhtaniemi 2000). 251 
This indicates that LH action in utero is not a prerequisite for fetal Leydig cell androgen and insulin-252 
like growth factor 3 (INSL3) production required for intrauterine testicular development and descent, 253 
and masculinization in male mice, highlighting the presence of additional safety mechanisms present 254 
for maintaining fetal Leydig cell function by a network of paracrine factors (El-Gehani, et al. 1998, 255 
Peltoketo, et al. 2011, Themmen and Huhtaniemi 2000). 256 
 257 
Testosterone replacement therapy in LuRKO animals leads to partial reversal of the hypogonadal 258 
phenotype, with achievement of full spermatogenesis; however, male mice remained sub-fertile due 259 
to poor accessory gland development and poor sexual behaviour (Pakarainen, et al. 2005). 260 
Abnormalities such as vigorous inflammation of the epididymis and the prostate were conspicuous in 261 
a proportion of the testosterone-treated mice. The incidence of low ejaculatory frequency and low 262 
sperm count in cauda epididymis were also observed. Whether testosterone replacement, or lack of 263 
sufficient androgen priming prepubertally prior to testosterone replacement, is responsible for these 264 
abnormalities, is not however clear. A striking physiological finding in the LuRKO mice is a late onset 265 
recovery of qualitatively full spermatogenesis around 12 months of age, when the passage of round 266 
spermatids to elongated spermatids can be found. This suggests that spermatogenesis can proceed 267 
qualitatively to completion with support of the basal LH-independent low intra-testicular testosterone 268 
present in the LuRKO testis (Zhang, et al. 2003), though a much higher threshold of testosterone may 269 
be required to induce qualitatively and quantitatively full spermatogenesis (Huhtaniemi, et al. 2006). 270 
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This finding was confirmed and extended in our recent study (Oduwole, et al. 2014), observing that a 271 
narrow margin separated the testosterone doses that activated peripheral male sexual androgen 272 
action and spermatogenesis. When extrapolated to humans, this may jeopardize the current approach 273 
to hormonal male contraception, as it will be practically impossible to define a single dose of 274 
testosterone that can suppress gonadotrophins and attain azoospermia. It is only a total abolition of 275 
intra-testicular testosterone action therefore, that can bring about total and complete suppression of 276 
spermatogenesis. 277 
 278 
 279 
2.4 Diminished FSH-FSHR activity 280 
Targeted ablation of bioactive FSH was achieved through deletion of exons 1, 2 and partial deletion of 281 
exon 3 of FSHβ (Kumar, et al. 1997). Phenotypic examination of FSHβ KO males showed reduced 282 
testis size, with decreased seminiferous tubule diameter and volume. However, Leydig cell 283 
populations were unaffected, and speculated qualitatively to be enhanced in number, however due to 284 
the reduced testis size, net Leydig cell number probably did not differ from WT littermates. Accessory 285 
sex glands were of comparable size to age-matched litter mates, consistent with comparable 286 
circulating serum testosterone and adequate Leydig cell number and function. Epididymal sperm were 287 
decreased by 75% in comparison to heterozygous and WT littermates, with motility decreased by 288 
40%, however no difference in viability was observed. Despite this, FSHβ KO animals were fertile, 289 
with normal serum LH, probably reflecting negative feedback from circulating testosterone. The 290 
maintenance of spermatogenesis and Sertoli cell function in the absence of FSH-activated FSHR is 291 
suggestive of potential testicular or extra-testicular paracrine factors that can compensate for FSH 292 
function in the testis, or that basal constitutive, ligand-independent FSHR activity is sufficient to 293 
maintain tonic testis function and spermatogenesis in male mice. 294 
 295 
The generation of FSHR knockout mice (FORKO) provided additional insight into the dependence of 296 
spermatogenesis on FSH (Abel, et al. 2000, Dierich, et al. 1998). As with FSHβ null males, FORKO 297 
males were fertile, with reduced testis size and decreased spermatogenesis. To examine key 298 
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differences in these models, a study was conducted to directly compare the phenotypes observed of 299 
FORKO and FSHβ GM mice (Baker, et al. 2003). Comparison of serum and intra-testicular 300 
testosterone showed a reduced level of circulating testosterone in FORKO animals that was not 301 
observed in FSHβ mouse model; yet both models exhibited diminished intra-testicular testosterone, 302 
indicating that local production of testosterone was impaired in both FORKO and FSHβ mice. Serum 303 
LH was elevated in FORKO animals, but not FSHβ animals. Interestingly, Leydig cell specific 304 
steroidogenic genes such as P450scc were diminished in the FORKO model, with decreased Leydig 305 
cell number to approximately 60% of control, suggesting a potential failure of Leydig cell proliferation 306 
and/or differentiation at puberty in FORKO animals that was not observed in FSHβKO animals. This 307 
effect is likely to be reflective of the decreased Leydig cell number observed in these animals and 308 
represents a key difference between these animal models. As both models were fertile,  these studies 309 
revealed that FSH action is not critical for maintenance of fetal Leydig cells, as shortly after birth, 310 
when the maintenance of these cells is critically dependent on gonadotrophin action. As FSHR is 311 
expressed solely in Sertoli cells, the action of FSHR on Leydig cell development must be via Sertoli 312 
cell secreted paracrine factors. Previously studies have implicated factors such as desert hedgehog 313 
and PDGF; however, to date nothing has conclusively been described to be the key factor(s) 314 
mediating these paracrine effects. It is likely that FSHR action mediates and ensures sufficient Sertoli 315 
cell activity for output of such trophic factors, and why spermatogenesis is impaired when either FSHβ 316 
or FSHR action is abrogated. Whereas FSHβ and FSHR KO male mice are fertile, there is some 317 
discrepancy in humans on the phenotype of men with inactivated FSH function.  The three men 318 
described with inactivating FSHβ mutations are all azoospermic (Layman, et al. 2002, Lindstedt, et al. 319 
1998, Phillip, et al. 1998), whereas the 5 men with inactivating FSHR mutations have oligozoospermia 320 
of variable severity (Tapanainen, et al. 1997).  This discrepancy can be resolved only through 321 
detection of new cases of these extremely rare mutations. 322 
 323 
3. Conclusions and perspectives 324 
The precise and coordinated control of gonadotrophin actions is crucial for the maintenance of male 325 
reproductive functions. Modifications in these functions can result in impaired fertility, with chronic 326 
dysregulation of gonadotrophin action often resulting in sub- or infertility. Our understanding of the 327 
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molecular mechanisms underlying human reproductive pathologies resulting from dysregulation of 328 
gonadotrophin action has been greatly enhanced by the generation and study of GM mouse models. 329 
The use of loss-of-function and gain-of-function models enables us to probe both modest and chronic 330 
changes in gonadotrophin secretion and gonadotrophin receptor activity, providing key detail in the 331 
developmental programming of males. These models identify how fundamental temporal control of 332 
the hypothalamic-pituitary-gonadal axis co-ordinates the development and function of the Sertoli and 333 
Leydig cells, necessary for the production and maintenance of full spermatogenesis.  334 
 335 
Comparative analysis of human and mouse reproductive pathologies shows us that Sertoli and Leydig 336 
cell function is highly sensitive to changes in gonadotrophin action, particularly LH/LHR. Clinical 337 
pathologies of enhanced LH action result in precocious puberty and Leydig cell hyperplasia, however 338 
normal fertility is usually maintained in humans, (Themmen and Huhtaniemi 2000), as observed with 339 
the CAM LHR mouse model (McGee and Narayan 2013). Many activating mutations of the LHR 340 
resulting in male reproductive pathologies have been identified, with the hotspots for activating 341 
mutations primarily localised to the G-protein coupling region of the receptor (Simoni, et al. 1998). It is 342 
interesting to note the disparity between GM models with constitutively active LHR and increased 343 
circulating LH/hCG in the timing of puberty. Precocious puberty was not observed in male mice with 344 
increased circulating LH/hCG despite the pre-pubertal increase in testosterone observed in many of 345 
the GM models discussed. This may reflect differences in the regulatory and membrane trafficking 346 
mechanisms controlling the expression and activity of WT and constitutively active LHR. Indeed, in 347 
hCGαβ mice, the WT LHR was subject to chronic down-regulation, whilst the constitutively active LHR 348 
may not be subject to such control. Unsurprisingly, only few activating mutations of FSHR have been 349 
identified in humans, probably due to the relatively benign phenotype observed (Casas-Gonzalez, et 350 
al. 2012, Gromoll, et al. 1996). Human males are fertile, mimicking the CAM FSHR mouse models 351 
described.  352 
 353 
Although there are many similarities between human reproductive pathologies originating from the 354 
dysfunction of gonadotrophin/gonadotrophin receptor, and mouse models of the same origin, it should 355 
be noted exceptions do exist and exact phenocopies of observed dysfunctions are not always 356 
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observed between these species. Of notable difference are the mechanisms of prenatal and 357 
prepubertal development and the relative importance and contributions of 358 
gonadotrophin/gonadotrophin receptor function, particularly LH/LHR, to testicular development in 359 
these processes. That said, GM mouse models have been excellent tools for dissecting the molecular 360 
mechanisms underlying reproductive pathologies, underpinning many research efforts to understand 361 
the physiology of the function of gonadotrophins and their receptors.  362 
 363 
With the ever growing sophistication in GM approaches, allowing similar point mutations with human 364 
genetic diseases, and more targeted spatial and temporal integration, replacement or deletion. With 365 
the coming of age of BAC transgenics, the use of mouse models provides new exciting opportunities 366 
to understand the mechanisms underlying reproductive pathologies. Whether mouse models can be 367 
used to test small molecule activators, inhibitors, or pharmacochaperones of gonadotrophin receptor 368 
function is yet to be investigated. However, in vivo proof of concept studies with pharmacochaperone 369 
of the LHR (Newton, et al. 2011) and of the GnRHR (Janovick, et al. 2013) presents exciting 370 
opportunities and future directions in drug design, with the use of in vivo models providing important 371 
hypothesis testing tools for researchers for many years to come. 372 
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